AXIM · Axim Biotechnologies, Inc.

Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.

Reporting Person acquired a convertible note, face value $156,750. The note is convertible into shares of the Issuer's common stock at a price of $0.02 per share for conversion into a total of 7,837,500 shares..

Reporting Person acquired an Amended Convertible Promissory Note in the face amount of $250,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.

Reporting Person acquired a Convertible Note, face value $35,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.

Reporting Person acquired a Convertible Note face $53,500. The Note is convertible into shares of the Issuers common stock at a price of $0.02 per share.

Reporting Person acquired a convertible note, face value $250,000. The note is convertible into shares of Issuer's common stock at a price of $0.02 per share.

Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.

Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.

Acquired from third party

Reporting Person acquired an option to purchase up to 1,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date.

Reporting Person acquired an option to purchase up to 1,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date.

Reporting Person acquired an option to purchase up to 1,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date.

Reporting Person acquired an option to purchase up to 5,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date.

Reporting Person acquired an option to purchase up to 500,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date.

Conversion of Note

This Note bears interest at a rate of 3% per annum. At the election of the Reporting Person, all principal and accrued interest under the Note may be converted into the Issuer's common stock at a converstion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Issuer's common stock in the ten (10) days prior to the date of conversion.

On May 6, 2021, Reporting Person voluntarily agreed to cancel the option to purchase 2,000,000 shares of the Issuer's common stock granted to Reporting Person on January 2, 2019.

Reporting Person acquired the option to purchase 500,000 shares of Issuer's common stock ("Option Shares") on May 13, 2020 (the "Date of Grant"). One-third of the Option Shares will vest on the Date of Grant; (iii) one-third of the Option Shares will vest six (6) months from the Date of Grant; and (iv) the remaining one-third of the Option Shares shall vest twelve (12) Months from the Date of Grant, provided, however, that there has not been a Termination of Service as of such date. In no event shall the Option become exercisable for any additional Option Shares after a Termination of Service.

Reporting Person acquired the option to purchase 500,000 shares of Issuer's common stock ("Option Shares") on May 13, 2020 (the "Date of Grant"). One-third of the Option Shares will vest on the Date of Grant; (iii) one-third of the Option Shares will vest six (6) months from the Date of Grant; and (iv) the remaining one-third of Option Shares shall vest twelve (12) Months from the Date of Grant, provided, however, that there has not been a Termination of Service as of such date. In no event shall the Option become exercisable for any additional Option Shares after a Termination of Service.

Reporting Person acquired the shares pursuant to a share exchange with the Issuer whereby Reporting Person exchanged 100% of the Sapphire Biotech, Inc. shares common stock held by Reporting Person for 6,000,000 shares of common stock of the Issuer.